PYXS (Pyxis Oncology, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PYXS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Jakob Dupont | Director | A | — | — |
| 2026-08-14 | Thomas Civik | Interim CEO | A | — | — |
| 2026-07-02 | Jakob Dupont | Director | MIXED | — | — |
| 2026-03-25 | RACHEL HUMPHREY | Director | A | — | — |
| 2026-03-25 | Santhosh Palani | Director | A | — | — |
| 2026-03-25 | Michael A Metzger | Director | A | — | — |
| 2026-03-25 | Freda C Lewis-Hall | Director | A | — | — |
| 2026-03-25 | RACHEL HUMPHREY | Director | Sell | — | — |
| 2026-03-25 | JOHN L FLAVIN | Director | A | — | — |
| 2026-03-25 | Darren S Cline | Director | A | — | — |
| 2026-03-25 | Jitendra Wadhane | Prin Fin & Acct Officer | A | — | — |
| 2026-03-25 | Jakob Dupont | Director | A | — | — |
| 2026-02-05 | Thomas Civik | Interim CEO | A | — | — |
| 2025-04-02 | Jitendra Wadhane | SVP, Chief Accounting Officer | A | — | — |
| 2025-04-02 | Freda C Lewis-Hall | Director | A | — | — |
| 2025-04-02 | RACHEL HUMPHREY | Director | A | — | — |
| 2025-04-02 | Santhosh Palani | Director | A | — | — |
| 2025-04-02 | Michael A Metzger | Director | A | — | — |
| 2025-04-02 | Lara Sullivan | President ,CEO & CMO | A | — | — |
| 2025-04-02 | Darren S Cline | Director | A | — | — |
| 2025-04-02 | Jakob Dupont | Director | A | — | — |
| 2025-04-02 | Thomas Civik | Director | A | — | — |
| 2025-04-02 | Pamela Ann Connealy | CFO & COO | A | — | — |
| 2025-04-02 | JOHN L FLAVIN | Director | A | — | — |
| 2024-12-23 | Pamela Ann Connealy | CFO & COO | A | — | — |
| 2024-12-23 | Lara Sullivan | Chief Executive Officer | A | — | — |
| 2024-12-23 | Jitendra Wadhane | SVP, Chief Accounting Officer | A | — | — |
| 2024-11-27 | Pamela Ann Connealy | CFO & COO | Buy | — | — |
| 2024-06-10 | Michael A Metzger | Director | A | — | — |
| 2024-06-07 | Santhosh Palani | Director | A | — | — |
| 2024-03-28 | Lara Sullivan | Chief Executive Officer | A | — | — |
| 2024-03-28 | Thomas Civik | Director | A | — | — |
| 2024-03-28 | JOHN L FLAVIN | Director | A | — | — |
| 2024-03-28 | RACHEL HUMPHREY | Director | A | — | — |
| 2024-03-28 | Freda C Lewis-Hall | Director | A | — | — |
| 2024-03-28 | Jakob Dupont | Director | A | — | — |
| 2024-03-28 | Pamela Ann Connealy | CFO & COO | A | — | — |
| 2024-03-28 | Darren S Cline | Director | A | — | — |
| 2024-03-28 | Jitendra Wadhane | SVP, Chief Accounting Officer | A | — | — |
| 2024-03-13 | Santhosh Palani | Director | A | — | — |
| 2023-12-29 | Ken Kobayashi | Chief Medical Officer | A | — | — |
| 2023-11-30 | Pamela Ann Connealy | CFO and COO | F | — | — |
| 2023-11-17 | Jitendra Wadhane | Chief Accounting Officer | A | — | — |
| 2023-09-28 | Pamela Ann Connealy | CFO and COO | Buy | — | — |
| 2023-09-27 | Pamela Ann Connealy | CFO and COO | Buy | — | — |
| 2023-09-27 | Jitendra Wadhane | Chief Accounting Officer | Buy | — | — |
| 2023-09-26 | Jakob Dupont | Director | A | — | — |
| 2023-09-25 | Pamela Ann Connealy | CFO and COO | Buy | — | — |
| 2023-09-25 | Jitendra Wadhane | Chief Accounting Officer | Buy | — | — |
| 2023-09-22 | Pamela Ann Connealy | CFO and COO | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 7,032,770 | — |
| — | — | 2,742,338 | — |
| — | President ,CEO & CMO | 2,412,423 | — |
| — | CFO & COO | 2,226,036 | — |
| — | Chief Medical Officer | 730,345 | — |
| — | Director | 668,854 | — |
| — | Prin Fin & Acct Officer | 512,882 | — |
| — | Director | 413,015 | — |
| — | Director | 251,405 | — |
| — | Director | 241,405 | — |
| — | Interim CEO | 221,886 | — |
| — | Director | 95,405 | — |
| — | Director | 66,831 | — |
| — | Director | 38,741 | — |
| — | Director | 6,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PYXS quote page; the site-wide leaderboard is on the insider transactions hub.